X
    X
    X
    X

    Biohaven Pharmaceutical Holding Company Ltd.

    A Locke Lord team represented Biohaven Pharmaceutical Holding Company Ltd. in its completion of the second tranche of its previously disclosed $80 million private financing. The financing was led by Venrock along with other leading biotech investors, including Vivo Capital, RA Capital Management, Aisling Capital, Rock Springs Capital, John W. Childs, Greg Bailey, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut Innovations and Litmore Capital. All investors who participated in the first tranche also participated in the second tranche. For more information, please see the Biohaven press release. The Locke Lord team was led by Douglas Gray (Providence) with assistance from Tamer Tullgren and Michael Conroy (both of Chicago) and Ralph Loren (Boston).
    Posted March 10, 2017

    Explore Additional Topics

    Disclaimer

    Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.
    A page from LockeLord.com I thought you'd find interesting